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Introduction
Sepsis is the most common cause of death in infants and 
children worldwide.1-4 Childhood pneumonia has an estimated 
incidence of 0.29 episodes per child-year in pre-developed and 
0.05 episodes per child-year in developed countries, making it 
the most common cause of pediatric sepsis; it is also the leading 
cause of mortality in children less than 5 y of age.5 Pre-developed 
countries with large populations of children bear the major bur-
den of pediatric sepsis. Of the approximately 156 million new 
cases of pneumonia per year worldwide, 151 million are esti-
mated to be in the developing world where a combination of con-
taminated water, poor sanitation, indoor air pollution, crowding, 
low birth weight, and insufficient immunization and nutrition 
allow pathogens to invade and multiply relatively unchecked in 
the body.5 This is why the first tier of the three tiered approach 
to the prevention of pediatric sepsis and its sequelae outlined in 
Figure 1 requires escalation of public health initiatives to remedy 
these issues. The second tier includes early identification and 
intervention to prevent sepsis progression from infection to sepsis 
to septic shock with end-organ damage. The third prevention tier 
includes intensive care supportive interventions to prevent sepsis-
related death and disability.
In this review, we limit our discussion to sepsis in term infants 
that have been exposed to the home environment through ado-
lescents under 18 y of age. We exclude much of the discussion of 
perinatal and neonatal sepsis which is covered elsewhere in this 
special issue. The purpose of this article is to highlight the major 
differences between adults and children in the diagnosis of sepsis, 
the response of the immune system to infection, and the manage-
ment of infants, children, and adolescents with life-threatening 
infections.
Pediatric Definitions of Sepsis, Severe Sepsis,  
and Septic Shock
When pediatricians use the term “sepsis”, they usually are 
referring to an infection that overwhelms the host causing capil-
lary leak, hypotension, and/or respiratory failure. Relatively stable 
children admitted to the hospital with complicated pneumonia, 
pyelonephritis, invasive cellulitis, or bronchiolitis are given these 
descriptive discharge diagnoses even though most could be given 
the diagnosis of “sepsis” according to the definitions published in 
2005 from the International Consensus Conference on Pediatric 
Sepsis (see Table 1). Those sepsis definitions were created to 
facilitate enrollment of children into clinical trials of anti-sepsis 
agents.6 They were modified only slightly from the consensus 
sepsis definitions created for adult patients originally published 
in 1992.7
Briefly, to be septic, a child must have a confirmed or sus-
pected infection and signs of a systemic response to that infec-
tion. Severe sepsis requires diagnosis of end organ system 
involvement. Septic shock requires cardiovascular dysfunction 
that is not resolved by initial f luid resuscitation. These defini-
tions were aimed at identifying sepsis in an early stage to facili-
tate early intervention, with the goal of stopping further spread 
of infection and preventing a severe life-threatening inflamma-
tory reaction to infection.6,7
One major difference in the definition of sepsis in children 
vs. adults are the age-specific cutoffs for physiologic and organ 
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Sepsis is the leading cause of death in children worldwide. 
Although the diagnosis and management of sepsis in infants 
and children is largely influenced by studies done in adults, 
there are important considerations relevant for pediatrics. This 
article highlights pediatric-specific issues related to the defi-
nition of sepsis and its epidemiology and management. we 
review how the capacity of the immune system to respond 
to infection develops over early life. we also bring attention 
to primary immune deficiencies that should be considered in 
children recurrently infected with specific types of organisms. 
The management of pediatric sepsis must be tailored to the 
child’s age and immune capacity, and to the site, severity, and 
source of the infection. it is important for clinicians to be aware 
of infection-related syndromes that primarily affect children. 
Although children in developed countries are more likely to 
survive severe infections than adults, many survivors have 
chronic health impairments.
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system-related laboratory parameters. The healthy pediatric car-
diovascular system can maintain cardiac output by employing 
extreme tachycardia for a prolonged period without inducing 
myocardial ischemia. Compared with adults, hypotension pres-
ents later in children and often portends imminent and poten-
tially non-reversible cardiovascular collapse.8 As a result, the 
pediatric consensus guidelines are designed to identify patients 
with compensated septic shock in the hope that early intervention 
will prevent cases of profound decompensation leading ultimately 
to death. Consequently, children whose physical exam reveals 
cold extremities with delayed capillary refill despite receipt of 
boluses of intravenous fluid are diagnosed with septic shock and 
are treated similarly to children with life-threatening vasopressor-
dependent decompensated septic shock.9 Although rigorous stud-
ies on the impact of these broadly encompassing sepsis definitions 
on clinical outcomes are lacking, there are some data to support 
that early recognition and treatment of sepsis can be life-saving 
for children in developed10 and pre-developed11 countries.
Response to Infection by the Developing  
Immune System
A child’s immune system is remarkably different from adults 
in terms of innate and adaptive immune function; in fact, full 
immunologic maturity is not reached until adolescence.12 The 
transition from a sterile, intrauterine environment, to the eco-
logically complex and changing microbiologic milieu that the 
infant must confront for the remainder of his or her lifetime, 
requires extreme shifts in immune function. Neonates are the 
most profoundly immune compromised, and their immune 
system is typified by comparatively poor innate and adaptive 
immune responses.13-19 In part, this gives them a survival advan-
tage because a relatively suppressed immune system allows the 
newborn to tolerate colonization of previously sterile skin and 
gastrointestinal tract with normal bacterial flora without trig-
gering an overwhelming inflammatory response.20 In neonates, 
phagocytes are less responsive to pathogen-associated molecular 
patterns (PAMPs) than adult cells, have diminished adhesion 
and extravasation activity, produce fewer pro-inflammatory 
cytokines, and have diminished antigen presentation activity to 
adaptive immune cells.21 Natural killer (NK) cells are less cyto-
toxic as well and complement levels are also only 10–70% of 
adult levels.16
Adaptive immunity is also suppressed in the very young. 
Although T cell levels are much higher in neonates than adults, 
their functionality is relatively poor, due in part to low production 
of interleukin-2 (IL-2). Helper CD4+ T cells are skewed toward 
Th-2 (humoral) responses in the neonate due to low produc-
tion of interferon-γ (IFNγ), and cytotoxic CD8+ T cells are less 
active.22 B cells, although also abundant in the neonate, are pre-
dominantly naïve, produce mostly IgM immunoglobulins (Igs), 
and are poorly responsive to capsular polysaccharides. By 2 y of 
age, adaptive and immune responses have largely approached 
those of healthy adult levels, but full immune competence is not 
truly reached until the teenage years.
The cumulative result of these deficits in immune function is 
that infants and some toddlers have markedly increased suscep-
tibility to severe infection from various organisms, particularly 
viruses and encapsulated bacteria. Susceptibility to severe viral 
infection is most prominent in children less than 2 y old due in 
part to unchecked viral replication caused by lower production 
of IFNγ and diminished cytotoxic lymphocyte responses.12 The 
Figure 1. Depiction of primary, secondary, and tertiary pediatric sepsis prevention efforts (modified, with permission from Dr Bala Totapally).
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primary mitigating factor during the first 6 mo of life is transpla-
centally acquired maternal antibody (primarily IgG and IgA), a 
reason for expanding the recommendations for maternal immu-
nization to include coverage of common pathogens associated 
with severe pediatric illness.23 Additionally, the use of protein-
polysaccharide conjugate vaccines can stimulate infant immune 
systems to produce protective levels of immunoglobulin to 
polysaccharide-encapsulated pathogens, including Haemophilus 
influenzae type b (Hib) and Streptococcus pneumoniae (S. pneu-
moniae).24,25 Such vaccines can even change nasopharyngeal 
carriage of pathogens, conferring a benefit to the community.26 
Unfortunately, vaccines to common viral pathogens, particularly 
influenza, are not approved for children less than 6 mo old and 
are poorly immunogenic in children <2 y old compared with 
older children and adults.27
Epidemiology and Clinical Manifestations  
of Pediatric Sepsis
The estimated overall prevalence of severe sepsis among chil-
dren living in the United States increased steadily from 0.56 
cases per 1000 children in 1995 to 0.63 cases per 1000 children 
in 2000, to 0.89 cases per 1000 children in 2005, with most of 
this increase due to newborn sepsis.3,28,29 For example, estimated 
prevalence of sepsis in US newborns is 9.7/1000 population, non-
newborn infants 2.25/1000, and the rates are 0.23 to 0.52/1000 
in subgroups of children 1–19 y of age.29 Such variation at the 
early extremes of life mirrors the markedly high rates reported 
in advanced elderly patients compared with younger adults.30 In 
fact, the clinical presentation of sepsis in 18- to 30-y-olds is very 
similar to the profile encountered in 12- to 17-y-olds and very 
different from patients aged 65 y and over. Also similar to adults, 
common pathogens causing sepsis in children differ not only by 
local geography but by age and medical co-morbidities.
In neonates presenting with late-onset sepsis, the most com-
mon bacterial pathogens include group B streptococci (GBS) 
and enteric gram-negative rods, especially Escherichia coli.31 
Peripartum prophylaxis protocols have reduced the incidence of 
GBS-related sepsis.32 Bordatella pertussis can cause a severe illness 
in young infants, characterized by recurrent episodes of gagging, 
apnea, cyanosis, and bradycardia and with high mortality in those 
that develop respiratory failure and pulmonary hypertension.33-36 
Table 1. Definitions of illnesses in the sepsis continuum
Clinical syndrome Criteria
Systemic inflammatory response 
syndrome (SiRS)
Must have at least 2 of the following of which at least one must be abnormal temperature or abnormal leukocyte 
count:
1. Abnormal heart rate (HR) defined as tachycardia (HR >2 SD above normal for age in the absence of external 
stimulus, drugs, or painful stimuli; or otherwise unexplained elevation over 0.5–4 h) or bradycardia (HR <10th 
percentile for age in absence of external vagal stimulus, drugs, congenital heart disease; or otherwise unexplained 
HR depression >0.5 h).
2. Tachypnea >2 SD above normal for age or mechanical ventilation for process other than anesthesia or 
underlying neuromuscular disease
3. Abnormal temperature defined as fever (core temperature >38.5 °C) or hypothermia (core temperature <36 °C).
4. Abnormal leukocyte profile with counts either elevated or depressed for age (not due to chemotherapy); or 
>10% immature neutrophils
infection
A suspected infection or one proven by positive culture, tissue stain, or molecular testing caused by any pathogen 
or a clinical syndrome associated with a high probability of infection. Acceptable evidence can include physical 
exam, laboratory, or radiologic findings
Sepsis SiRS resulting from or occurring in the presence of proven infection
Severe sepsis
Sepsis plus the following: cardiovascular organ dysfunction, acute respiratory distress syndrome (ARDS), or two or 
more other organ dysfunctions
Septic shock
Sepsis (defined above) and the following signs of cardiovascular organ dysfunction that remain after initial fluid 
resuscitation (40 ml/kg intravascularly in ≤1 h):
• Decrease in BP (hypotension) <5th percentile for age or systolic BP >2 SD below normal for age; OR
• Need for vasoactive drug to maintain BP in normal range (dopamine >5 µg/kg/min or epinephrine, or 
norepinephrine at any dose); OR
• At least two of the following
 - Unexplained metabolic acidosis: base deficit >5.0 meq/L;
 - increased arterial lactate >2 times upper limit of normal
 - Oliguria: urine output <0.5 mL/kg/h
 - Prolonged capillary refill: >5 s
 - Core to peripheral temperature gap >3 °C
Adapted from reference 6.
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H. influenzae type b, previously one of the most common causes 
of bacterial sepsis in children <5 y old, and still a major cause of 
preventable pediatric mortality worldwide,37 is now uncommon 
in the developed world due to widespread use of the conjugate 
vaccine in infants.38,39 Similarly, although S. pneumoniae is still 
the leading cause of hospitalization for pneumonia in childhood, 
conjugate 7-valent and 13-valent S. pneumoniae vaccine use has 
decreased the incidence of invasive bacterial infection by as much 
as 76%.40,41
Another bacteria often isolated from infants and young chil-
dren with severe sepsis in developed countries is Neisseria men-
ingitidis.3 N. meningitidis infection, causing meningococcemia, 
peaks in a unique bimodal age distribution, first in infants and 
toddlers and again in adolescents where outbreaks can occur 
at schools, thus prompting recommendations for administer-
ing conjugate meningococcal vaccine for teenagers and debate 
among experts regarding potential vaccine strategies for infants.42 
Meningococcemia most commonly occurs in previously healthy 
children, usually presenting with the sudden onset of fever, vom-
iting, headache, difficulty concentrating, and severe myalgias.43 
The classic triad of fever, meningismus, and altered mental status 
occurs in only 27% of children with meningococcemia. Up to 
25% of children with meningococcemia will progress to develop 
purpura fulminans, which is caused by microvascular thrombosis 
that leads to tissue necrosis, skin infarction, and hemorrhage.44 
Children developing gangrene and tissue necrosis can require 
extensive amputations.45 Other causes of purpura fulminans 
include S. pneumoniae, S. pyogenes, and varicella.
Additional bacterial pathogens of concern include S. aureus 
and Streptococcus pyogenes (group A strep or GAS) which can lead 
to severe necrotizing pneumonias accompanied by septic shock in 
otherwise healthy children. S. aureus is of particular concern as 
it increasingly accounts for pediatric hospitalization for invasive 
disease and because the rising incidence of methicillin-resistant 
(MRSA) strains in communities impacts empiric antibiotic selec-
tion and longitudinal management.46 Increasing antimicrobial 
resistance among gram-negative enteric bacteria and opportu-
nistic gram-negative pathogens (e.g., Pseudomonas, Acinetobacter, 
Burkholderia spp.), also raises the risk of mortality among infected 
children by delay of effective antibiotic treatment and/or from 
increased virulence that is observed in some multidrug-resistant 
organisms.47,48 Such organisms are most commonly identified 
in children hospitalized for prolonged periods with persistent 
indwelling devices such as intravascular catheters or tracheosto-
mies,49 and in oncology and other immune-suppressed patients 
who have had multiple courses of broad-spectrum antibiotics.50 
Among such children with multiple exposures to hospitals and 
other healthcare settings, nosocomial pathogens, including coag-
ulase-negative staphylococci (CONS) and MRSA, should also be 
considered.51,52 Neutropenic patients are at high risk of mortal-
ity from gram-negative rod bacteremia (including Pseudomonas 
aeruginosa) and α-hemolytic streptococci (particularly in cases 
of mucositis).51,53
Viral-induced sepsis can result from a variety of viruses influ-
enced by age and underlying immune status. Influenza is one of 
the most common cause of viral sepsis in children leading to one 
of the highest rate of hospitalizations and the highest number 
of deaths.54 Although vaccination may prevent the majority of 
influenza-related severe respiratory infections,55 low vaccination 
rates, decreased vaccine response in young children, and periods 
of poor match between circulating viruses and influenza vaccine 
lead to an ongoing healthcare burden.56 Although parainfluenza 
virus most commonly stays in the upper airway causing croup 
mostly in healthy children, it can cause severe pneumonia in the 
very young and in children with compromised immune or respi-
ratory symptoms57 as can adenovirus.58
Bronchiolitis, a viral lower respiratory tract infection syndrome 
characterized by hyperinflation, increased mucous production, 
air trapping, and wheezing, affects 1–2% of infants worldwide.59 
Although respiratory syncytial virus (RSV) is identified in the 
majority of infants hospitalized for bronchiolitis in the developed 
world,60 very few of these infants die if given supportive care. 
Human metapneumovirus and rhinovirus are increasingly iden-
tified as a cause of hospitalization for bronchiolitis in infants.60 
Risk factors for life-threatening bronchiolitis and viral sepsis 
include premature birth, chronic lung disease, congenital cardiac 
abnormalities, and primary immunodeficiency.61
Viral–bacterial co-infection occurs in up to 23% of cases of 
severe pneumonia, resulting in a higher likelihood of respiratory 
failure and septic shock.62 The viral infection is thought to pre-
cede and predispose children to bacterial invasion. For example, 
MRSA was recently reported to be associated with mortality in 
previously healthy children infected with influenza,63 especially 
in the 2009 influenza pandemic where this fatal coinfection was 
a strong mortality predictor causing unrelenting destruction of 
lung despite appropriate antibiotics.64 Although the mechanism 
underlying viral–bacterial coinfection is unclear, this highest risk 
subgroup of children with influenza–S. aureus co-infection were 
shown in one study to be more likely than those with influenza 
alone to have cytokine storm that coexisted with a decreased 
monocyte response to ex vivo stimulation with lipopolysac-
charide (aka “immunoparalysis”).65 Neonates are susceptible 
to overwhelming viral sepsis from herpes simplex virus (HSV), 
enterovirus, and parechoviruses,66-68 and profoundly immune-
compromised children from cancer or HIV can develop sepsis 
from HSV, acute cytomegalovirus, adenovirus, or Epstein–Barr 
virus infections)69-71 Aside from influenza virus, older children 
and adolescents with healthy immune and cardiorespiratory sys-
tems are rarely hospitalized for viral sepsis.
Diarrheal diseases are another major cause of sepsis in infants 
and children, especially in the pre-developed world. Public health 
sanitation interventions and availability of clean water are essen-
tial and highly effective in decreasing sepsis-related mortality in 
children worldwide. In developed countries, rotavirus can lead 
to a profound diarrhea and sepsis-like picture in very young chil-
dren prompting development of the rotavirus vaccine.72
Several other pathogens cause sepsis primarily in pre-devel-
oped countries. Dengue virus, a mosquito-borne flavivirus 
endemic to many tropical countries, causes a sepsis syndrome 
typified by capillary leak and disseminated intravascular coagu-
lation (DIC).73 Malaria—particularly Plasmodium falciparum—
can cause sepsis in young children and HIV-infected children; 
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sepsis is often seen in association with cerebral malaria present-
ing with symptoms of altered mental status, convulsions, and 
acidosis.74,75 Burkholderia pseudomallei, or meliodosis, seen in 
southeast Asia, can present with pulmonary symptoms and 
fever.76
Less common causes of sepsis should be considered as well, 
depending on risk factors. Fungal pathogens, particularly 
Candida species, cause up to 10% of severe septic shock in chil-
dren.3 Depending on geographic exposures, tick-borne diseases 
that can present as encephalitis meeting criteria for sepsis include 
Rocky Mountain Spotted Fever and ehrlichiosis.77 Salmonella 
species should be considered, particularly in children with func-
tional asplenia and those who are malnourished.78 In endemic 
areas, children with immune compromise and/or asplenia are at 
risk for babesiosis. Finally, it is important to note that, despite 
advances in microbiologic detection methods, the underly-
ing cause of sepsis remains unknown in up to 75% of pediatric 
cases.79
Primary and Acquired Immune Deficiency in Sepsis
Although neonates, infants, and young children are at 
increased risk for severe infection and sepsis compared with older 
children and adolescents, it is critical to recognize recurring pat-
terns of infection or severe clinical presentations suggesting that 
the child may have an underlying immune deficiency.80 A thor-
ough evaluation for a primary immune deficiency should include 
a detailed medical history that includes gestation, birth, growth, 
development, and immunizations, a family history, and a history 
of prior infections with special attention to pathogens identified 
and sites of infection. Screening labs can then be considered in 
conjunction with specialist consultation.81 Table 2 lists patho-
gens and clinical presentations associated with selected primary 
immune deficiency categories.
Human immunodeficiency virus increases the risk for sepsis 
in infected children substantially, although this risk is mitigated 
with antiretroviral therapy use.82-84 Similar to severe combined 
immune deficiency syndromes (SCID) and other disorders 
of T-cell function, sepsis can arise from infection with typical 
pathogens (e.g., S. pneumoniae), from invasive fungal infections 
or from opportunistic infection such as disseminated myco-
bacterial infection. In pre-developed countries, HIV infection 
is significantly associated with disseminated infection from 
Mycobacterium tuberculosis as well.84
Management of Sepsis in Infants and Children 
Compared with Adults
In part, due to the challenge of performing clinical trials 
in children with sepsis-related critical illness85 there are a pau-
city of strong data from rigorous and appropriately-powered 
clinical trials to guide the management of children with severe 
sepsis. Consequently, published recommendations for sepsis 
management in infants and children closely mimic those for 
adult patients. The Surviving Sepsis Guidelines (2012 update) 
lists few differences in pediatric management recommendations 
from those in adults and these are summarized in Table 3.86 Of 
primary importance, as in adult patients with sepsis, is to pro-
vide empiric antimicrobial therapy that treats potential causative 
pathogens based on a patient’s age and exposure history.87 Full 
discussion of the details of managing sepsis in children is beyond 
the scope of this article, but we do note a few unique aspects of 
treating the pediatric septic patient. One major difference in how 
children with refractory septic shock and/or refractory hypox-
emia from severe respiratory tract infection are clinically man-
aged compared with adults is a higher use of extracorporeal life 
support (ECLS) as rescue therapy.86 ECLS survival rates in chil-
dren with severe pneumonia and refractory septic shock reported 
by the ELSO registry are 50% and are above 80% in those who 
have single organ failure (refractory respiratory failure) triggered 
viral infection.88
Additionally, early use of goal-directed therapeutic targets, 
such as rapid and repeated fluid resuscitation, and early insti-
tution of vasopressor support when fluid resuscitation fails, are 
associated with decreased mortality in meningococcemia,89 
This aggressive fluid resuscitation strategy has been extrapo-
lated to pediatric treatment recommendations for other causes 
and presentations of pediatric sepsis.10,11,90,91 Recent data from 
the FEAST trial of fluid management in over 3000 African chil-
dren showed markedly higher mortality those with compensated 
shock randomized to receive repeated boluses of saline or albu-
min compared with children who did not receive fluid boluses.92 
Although these children had high rates of malaria and severe 
anemia, secondary analyses did not identify them as contributors 
to the increased mortality in the children receiving fluids.93 The 
results of the FEAST trial have raised concerns internationally 
as to whether the aggressive use of fluid boluses even in devel-
oped countries might harm children with compensated shock.94 
Positive fluid balance has been associated with worse clinical out-
come in other studies of critically ill children, many of whom had 
sepsis.95-98 Table 4 lists multiple pediatric sepsis resources that 
provide additional recommendations regarding management.
Factors Influencing Pediatric  
Sepsis-Related Mortality
Although children <12 mo old have the highest risk of death 
from sepsis, much of this mortality is driven by the high inci-
dence of sepsis and the high rate of sepsis-related mortality in 
infants born very prematurely.3 Compared with older children, 
infants have the highest incidence of severe sepsis but much of 
it is viral and most will survive hospitalization. A higher mortal-
ity among male patients, suggested by studies in adult patients 
and animals, appears less prominent in children, although males 
are more likely to be hospitalized in infancy for severe infec-
tions.3,99,100 The incidence of malignancies and other chronic 
respiratory and cardiac conditions in children rises with age and 
contributes to sepsis-related mortality; the majority of older chil-
dren hospitalized with sepsis have underlying conditions impair-
ing their immune or cardiorespiratory systems.3
Site of infection also is related to likelihood of severe sepsis and 
death, with endocarditis and CNS infections associated with the 
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highest mortality rates (21.1% endocarditis, 17.1% CNS infec-
tions).3 Certain organisms are associated with worse prognosis, 
particularly fungi, and infections with antibiotic-resistant bac-
teria, including MRSA, gram-negative bacilli, and nosocomial 
pathogens.101-103 The extent of systemic involvement is also very 
important, as children who develop multiple organ system failure 
from sepsis have the lowest likelihood of surviving.3,104 Survival 
from sepsis, after adjusting for sepsis severity, is usually higher 
in children compared with adults. In a large pediatric clinical 
trial of recombinant human-activated Protein C in pediatric sep-
tic shock,105 mortality in the cohort of the the septic children 
enrolled (who were all mechanically ventilated and on vasopres-
sors) was approximately 17% compared with rates of 26–34% in 
clinical trials in adult sepsis and septic shock patients who did not 
have to be mechanically ventilated to gain entry.106,107
Although there are a paucity of national-level data on pediat-
ric sepsis outcomes from pre-developed countries,108 the World 
Federation of Pediatric Intensive and Critical Care Societies 
(WFPICCS) is working to change this through their global 
sepsis initiative (http://www.wfpiccs.org). Sepsis mortality has 
been reported in studies of dengue fever and specific infections 
but few trials in pre-developed countries have enrolled a hetero-
geneous group of children with sepsis.109 Over half of African 
children in the multicenter FEAST trial that presented with 
hypotension and decompensated shock died.110 In the group 
that included mostly children with compensated septic shock, 
Table 2. infections and infection-related syndromes associated with underlying immune deficiencies
Underlying type of 
immune deficiency
Example/etiology Associated infections and infection-related syndromes
Agammaglobulinemias
All ig isotypes deficient or absent X-linked agammaglobulinemia
Hib, S. pneumoniae (recurrent respiratory infections)
Giardia lamblia, rotavirus (chronic diarrhea)
enterovirus (chronic meningoencephalitis)
One or more (but not all) ig isotypes 
reduced/absent
Common variable immune deficiency 
(CviD)
Hib, S. pneumoniae (recurrent respiratory infections)
C. jejuni, Salmonella spp., Giardia (gastrointestinal infections)
Autoimmune disease
immunoglobulin class switch 
recombination disorders
Hyper-igM syndromes
Recurrent/severe sinopulmonary infections
P. jirovecii infection in first year of life
Cryptosporidium, Giardia
Autoimmune disorders
Complement deficiencies
Common pathway C3
Bacteremia or sepsis from H. influenzae, S. pneumoniae, meningococci, 
encapsulated bacteria
Mannose-binding lectin (MBL) 
pathway
Polymorphisms with low MBL levels Meningococci, S. pneumoniae, among others
Late complement defects and 
alternative pathway defects
C5–C9, properdin Sepsis, disseminated infection from meningococci, N. gonorrhoeae
Phagocyte disorders
Absent/defective oxidative burst Chronic granulomatous disease (CGD)
Burkholderia cepacia pneumonia, Nocardia spp., Aspergillus spp., 
S. aureus infections, liver abscesses
Decreased/absent hypochlorous acid 
production
Myeloperoxidase deficiency invasive Candida spp. infections
Lysosomal packaging disorder Chediak–Higashi syndrome
Recurrent respiratory, skin, and soft tissue infections with S. aureus, 
oculocutaneous albinism
Cell-mediated immunity
T- and B-cell dysfunction
Severe combined immunodeficiency 
syndrome (SCiD)
Opportunistic infections (incl. P. jirovecii), fungal infections, invasive 
bacterial infections, persistent, severe viral infections (RSv, vZv, HSv, 
CMv), occurring in infancy
T-cell and NK cell disorders
Ataxia–telangiectasia Severe sinopulmonary infections, ± opportunistic infections
Hyper ig-e syndrome
Recurent pneumonias from S. aureus, H. influenzae, S. pneumoniae, 
severe eczema
NK cell deficiency Severe HSv, vZv, CMv infection beyond infancy
Summarized from reference 114. Definitions: ig, immunoglobulin; Hib, H. influenzae type b; RSv, respiratory syncytial virus; vZv, varicella zoster virus; HSv, 
herpes simplex virus; CMV, cytomegalovirus; NK, natural killer.
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mortality was 7.3–10.6% in the first 48 h after presentation and 
8.7–12.2% at 4 weeks depending on the study arm. In addition, 
approximately 2% of survivors had severe neurologic sequelae.92
Summary
In this brief review, we have highlighted some of the major 
differences between the diagnosis, epidemiology, host immune 
response, treatment, and outcome of infants and children com-
pared with adults. As shown in Figure 1, decreasing the high bur-
den of sepsis in the pediatric population requires a multi-tiered 
approach. Prevention of sepsis is paramount and public health 
initiatives have been shown to be high-impact, cost-effective 
interventions. Early recognition of sepsis and initial management 
in the outpatient and hospital wards are essential for preventing 
progression to more severe forms. Supportive intensive care unit 
interventions such as mechanical ventilation, vasopressor infu-
sions, and continuous monitoring modalities are essential for pre-
venting sepsis-related disability and death.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Table 3. A capsule summary of pediatric-specific consensus recommendations for sepsis management from the 2012 Surviving Sepsis Guidelines86 and 
Pediatric Advanced Life Support Guidelines111
Initial Resuscitation: Pediatric Specific Considerations
1. infants anatomically have low pulmonary functional residual capacity and can desaturate very quickly. Supplemental oxygen should be delivered via 
face mask or nasal cannula or other devices to children with septic shock even if oxygen saturation levels appear normal with peripheral monitoring 
devices.
2. Peripheral intravenous access is often difficult to obtain in hemodynamically unstable infants and young children. if unable to obtain peripheral 
intravenous access quickly, early use of intraosseus access is recommended for fluid resuscitation, inotrope infusion and delivery of antibiotics when 
central venous access is not easily obtainable. if mechanical ventilation is required then cardiovascular instability during intubation may be less likely 
after appropriate cardiovascular resuscitation.
3. The American College of Critical Care Medicine-Pediatric Life Support (ACCM-PALS) guidelines112 are recommended for the management of septic 
shock in children.
Antibiotics and Source Control
1. empiric antibiotics should be administered within the first hour of determining that the patient has severe sepsis. Obtaining blood cultures prior to 
antibiotics is preferred, when possible, but should not delay antibiotic administration.
 a. The empiric drug choice must be tailored to epidemic and endemic ecologies and consideration for treatment of resistant organisms is essential.
 b. Clindamycin and anti-toxin therapies for toxic shock syndromes with refractory hypotension are recommended.
2. early and aggressive source control is essential. Because infants and young children have difficulty communicating the location of their pain, 
radiologic imaging is an essential part of the workup in children with severe sepsis.
Fluid Resuscitation
1. in the industrialized world with access to inotropes and mechanical ventilation, initial resuscitation of hypovolemic shock begins with infusion of 
isotonic crystalloids (or albumin equivalent) with repeated boluses of up to 20 mL/kg of crystalloids (or albumin equivalent) over 5–10 min, titrated to 
reversing hypotension, increasing urine output, and attaining normal capillary refill, peripheral pulses, and level of consciousness.
 a. in a child with hepatomegaly or rales, early inotropic support should be implemented, and fluid resuscitation carefully titrated.
2. in children with compensated shock in resource-limited settings without access to inotropes or mechanical ventilation, fluid boluses may be harmful.92 
Blood transfusion should be considered in patients with compensated shock who are profoundly anemic.
Extracorporeal Membrane Oxygenation (ECMO)
1. Consider eCMO for refractory pediatric septic shock with respiratory failure.
Blood Products and Plasma Therapies
1. Hemoglobin targets are similar in children as in adults. in hemodynamically unstable children in shock on vasopressor infusions, hemoglobin levels of 
≥10 g/dL are targeted. in stable critically ill children, a lower hemoglobin target of ≥7.0 g/dL is recommended.113
2. Similar platelet transfusion targets in children as in adults.
3. Consider plasma therapies in children to correct sepsis-induced thrombotic purpura disorders, including progressive disseminated 
intravascular coagulation, secondary thrombotic microangiopathy, and thrombotic thrombocytopenic purpura.
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